[go: up one dir, main page]

WO2005030183A3 - A method for the preparation of atorvastatin calcium tablets - Google Patents

A method for the preparation of atorvastatin calcium tablets Download PDF

Info

Publication number
WO2005030183A3
WO2005030183A3 PCT/TR2004/000042 TR2004000042W WO2005030183A3 WO 2005030183 A3 WO2005030183 A3 WO 2005030183A3 TR 2004000042 W TR2004000042 W TR 2004000042W WO 2005030183 A3 WO2005030183 A3 WO 2005030183A3
Authority
WO
WIPO (PCT)
Prior art keywords
atorvastatin calcium
preparation
calcium tablets
formulation
tablets
Prior art date
Application number
PCT/TR2004/000042
Other languages
French (fr)
Other versions
WO2005030183A2 (en
Inventor
Farshi Farhad Seyed
Original Assignee
Biofarma Ilac Sanayi Ve Ticare
Farshi Farhad Seyed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofarma Ilac Sanayi Ve Ticare, Farshi Farhad Seyed filed Critical Biofarma Ilac Sanayi Ve Ticare
Publication of WO2005030183A2 publication Critical patent/WO2005030183A2/en
Publication of WO2005030183A3 publication Critical patent/WO2005030183A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a stabile oral formulation of a HMG-CoA reductase inhibitor compound, atorvastatin calcium, with improved bioavailability. Manufacturing process and composition of such formulation is also disclosed in this invention.
PCT/TR2004/000042 2003-09-26 2004-09-24 A method for the preparation of atorvastatin calcium tablets WO2005030183A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2003/01614 2003-09-26
TR2003/01614A TR200301614A2 (en) 2003-09-26 2003-09-26 New method for the preparation of atorvastatin calcium tablet formulation

Publications (2)

Publication Number Publication Date
WO2005030183A2 WO2005030183A2 (en) 2005-04-07
WO2005030183A3 true WO2005030183A3 (en) 2005-09-09

Family

ID=34388831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2004/000042 WO2005030183A2 (en) 2003-09-26 2004-09-24 A method for the preparation of atorvastatin calcium tablets

Country Status (2)

Country Link
TR (1) TR200301614A2 (en)
WO (1) WO2005030183A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070520A1 (en) 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
KR101950907B1 (en) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 Oral preparation comprising liphophilic drug and a oilproof material coated solid formulation
CN106420645A (en) * 2016-11-24 2017-02-22 浙江新东港药业股份有限公司 Calcium tablet containing atorvastatin and preparation method
CN108421045B (en) * 2018-04-02 2021-09-24 北京海晶生物医药科技有限公司 Atorvastatin calcium composition, preparation and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0789875A (en) * 1993-09-20 1995-04-04 Dai Ichi Seiyaku Co Ltd Tablet free from disintegration delay
US5686104A (en) * 1993-01-19 1997-11-11 Warner-Lambert Company Stable oral CI-981 formulation and process of preparing same
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001080822A2 (en) * 2000-04-20 2001-11-01 Ethypharm Effervescent granules and methods for their preparation
WO2002072073A2 (en) * 2001-03-14 2002-09-19 Lek Pharmaceutical And Chemical Company D.D. Pharmaceutical formulation comprising atorvastatin calcium

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686104A (en) * 1993-01-19 1997-11-11 Warner-Lambert Company Stable oral CI-981 formulation and process of preparing same
JPH0789875A (en) * 1993-09-20 1995-04-04 Dai Ichi Seiyaku Co Ltd Tablet free from disintegration delay
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001080822A2 (en) * 2000-04-20 2001-11-01 Ethypharm Effervescent granules and methods for their preparation
WO2002072073A2 (en) * 2001-03-14 2002-09-19 Lek Pharmaceutical And Chemical Company D.D. Pharmaceutical formulation comprising atorvastatin calcium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 07 31 August 1995 (1995-08-31) *

Also Published As

Publication number Publication date
WO2005030183A2 (en) 2005-04-07
TR200301614A2 (en) 2005-10-21

Similar Documents

Publication Publication Date Title
WO2005014539A3 (en) Pyrrole-based hmg-coa reductase inhibitors
IL183920A0 (en) A COMBINATION FORMULATION OF A 3-HYDROXY-3 - METHYL GLUTARYL CoA REDUCTASE INHIBITOR AND AN ANTIHYPERTENSIVE AGENT AND PROCESSES FOR THE PREPARATION THEREOF
EP1205189A3 (en) Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
IL163279A (en) Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
HUP0402590A3 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
WO2006134482A8 (en) Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
AU2002337158A1 (en) Method for the production of adhesive stamped products
WO2004050618A3 (en) Crystalline form f of atorvastatin hemi-calcium salt
AU2002349353A1 (en) Method for the production of pressure-sensitive adhesive stamped products
WO2005030183A3 (en) A method for the preparation of atorvastatin calcium tablets
AU2002306734A1 (en) Inhibitors of plasmepsins
AU2003266397A1 (en) Method for the production of polyisobutene
WO2005105079A3 (en) Novel imidazoles
AU2003289165A1 (en) Calcium phosphate base particulate compound, process for producing the same and composition comprising the compound
WO2007071012A8 (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor
AU2002356423A1 (en) Process for the preparation of amorphous atorvastatin calcium
AU2003246098A1 (en) Oxamidination process of carbonyl compounds
AU2003243432A1 (en) Process of making phosphordiamidite compounds
WO2006059210A3 (en) Fused bicyclic pyrrols as hmg-coa reductase inhibitors
HK1072421A (en) Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
AU2003263155A1 (en) Method for manufacture of dihydroisobenzofuran derivatives
AU2002337600A1 (en) Fed batch solid state fermentation for the production of hmg-coa reductase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase